Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. - Wikidata - awgldk - TriplyDB

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.

http://www.wikidata.org/entity/Q37248327

about

Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea Management of the adverse effects of lenalidomide in multiple myeloma.Lenalidomide for the treatment of relapsed and refractory multiple myeloma.Practical approaches to the use of lenalidomide in multiple myeloma: a canadian consensus.Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.Total cost comparison in relapsed/refractory multiple myeloma.Lenalidomide in multiple myeloma-a practice guideline.Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data.Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial Lenalidomide in multiple myeloma: current role and future directions.The Belgian 2010 consensus recommendations for the treatment of multiple myeloma.Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement.Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions.Guidelines for the diagnosis and management of multiple myeloma 2011.Managing multiple myeloma in the elderly: are we making progress?Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents.Safety and efficacy of lenalidomide in relapsed or refractory multiple myeloma.Lenalidomide in multiple myeloma: Current status and future potential.Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma.Current treatment landscape for relapsed and/or refractory multiple myeloma.Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients.Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.Efficacy of lenalidomide in association with cyclophosphamide and dexamethasone in multiple myeloma patient with bilateral retro-orbital localisation Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients.An update on the use of lenalidomide for the treatment of multiple myeloma.Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.Using pharmacy management systems for research: survival outcomes for lenalidomide in multiple myeloma in the clinical setting.Current treatment strategies with lenalidomide in multiple myeloma and future perspectives.American society of hematology.Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations.Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide.Trial Watch: Lenalidomide-based immunochemotherapy.Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone.Lenalidomide in multiple myeloma.Peroxisome proliferator-activated receptor gamma agonists potentiate the cytotoxic effect of valproic acid in multiple myeloma cells.Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.

P2860

Q26992002-10D92C96-7C8F-463C-96A3-13EAE466EE60 Q33394632-51AFCDE3-0ADF-4483-899B-7349D7356FF0 Q33403183-195014FC-73F9-4536-AEC4-93ED87ACC21C Q33404007-3A2F6EFB-5AA1-4ABE-8576-9415F56AD7F6 Q33408056-5D2B9825-C250-4945-ADB6-8474C7B285C2 Q33408494-6A2D3956-AF10-4263-AEE8-E32D80F3F55B Q33437691-375BE514-AB41-4E8C-BC54-470DF6F60DB2 Q34088340-62A3BE00-9C60-471C-8B0B-BF5352973030 Q34656086-4DA566A3-346A-470A-85D4-7DBACAF8DCBB Q36065299-333418A9-7B9A-4DFD-9B14-EF33DBC28E57 Q36109802-1FF71890-5A4A-4232-B8F3-52AA58BF55AF Q36138646-53758794-9148-4FA4-B3EC-E2E5643E69C2 Q37704401-8A36EF3F-4F21-49FA-859C-0C82CEFF29F1 Q37800884-2E24358F-E4F9-4355-88B0-E20E2CCB6EBC Q37835695-E91FFFD9-3FAD-4EC2-83A9-86D3C3E53707 Q37858523-9C07B64A-E6F9-4BE6-9BF4-0F8308BC2F23 Q37862262-68FA4907-E909-4627-A9D5-675D4A2179C1 Q37875193-45ED7345-0DCC-4D04-818D-2319BACBEFD1 Q37888716-11166C10-70AE-445F-9FEF-0D9582E0696C Q37949201-6AE54A03-9D25-428E-BB84-7C8154EF288C Q37976672-0DBC7592-88F5-4CF5-8390-BEC1FEF8A9CE Q38013995-015E4E36-807B-4837-9B6B-A37F982B7D99 Q38031989-DB28002D-8208-4245-8501-31BF6B78ED8A Q38271032-7BA6AF64-8BE8-4AF3-A2D1-40A8170EFFBF Q38446990-D56003B3-84A4-45FD-98A2-AB60031FFC84 Q38462720-54361D1A-E454-4E9D-BE03-DC1EF801F10E Q38496485-A5D5DCF3-8B7E-486B-B0B9-F094CBB1F9DD Q38530066-9EF58A26-7198-49DC-86D0-C9610D843C41 Q38545607-5EBDFC6A-7DB4-4F98-A087-F31083B636FB Q38672091-7659E4C9-0059-4DA0-9FCF-337822172653 Q38749573-F5C4B7E3-2A3E-4A01-95A8-598011AA7A08 Q39524467-C057010C-3B11-4151-9A63-9F03090E942A Q39890742-AC5C791A-3724-42AB-A565-43505FC1F956 Q41602673-6CCB3782-F5C6-42E5-98C6-3BFA3FBCA21A Q41655429-57075056-5162-4692-ABD1-84FB5A7509B7 Q42737828-161A15E5-FEFF-4611-8E4C-9BA113D04937 Q43195076-9AA673CA-72D6-48CC-B761-1A7B62C0E496 Q43247044-8D6C0983-5517-4470-8D28-E850A7EE4534 Q43269070-4BE427EE-706F-4919-892B-6DA0C4EA56DF Q43726973-F0FA796B-128A-4353-A2DF-F9960C86A19C

P2860

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.

http://www.wikidata.org/entity/Q37248327

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 19 March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Lenalidomide in combination wi ...... r refractory multiple myeloma.

@en

Lenalidomide in combination wi ...... r refractory multiple myeloma.

@nl

type

label

Lenalidomide in combination wi ...... r refractory multiple myeloma.

@en

Lenalidomide in combination wi ...... r refractory multiple myeloma.

@nl

prefLabel

Lenalidomide in combination wi ...... r refractory multiple myeloma.

@en

Lenalidomide in combination wi ...... r refractory multiple myeloma.

@nl

P1433

Q37248327-5CBFBCAA-9ACA-4C53-96DE-E9B487D66685

P1476

Q37248327-1DA9A659-24F5-4C8D-92CF-BAE44D87BCE8

P2093

Q37248327-0F14D4CD-F58A-4B3C-A791-2F2024FEBB4B

Q37248327-160BE34F-5A91-46F3-9353-1DE767277AA0

Q37248327-56DFE563-3A4E-43E6-BC42-22041960A52E

Q37248327-5E4C9250-77AB-413D-A589-678F7D6A53FD

Q37248327-646DCC01-43B2-4AAC-A4A8-70DBD92AD66D

Q37248327-9D488EF3-9E7F-4B60-9033-903A20FE4130

Q37248327-B3C0935F-DF45-4A46-A6A3-ABB9962DF4DF

Q37248327-C27E1A61-C8F7-42A5-B25E-929460181EAE

P2860

Q37248327-0FBE2098-C993-431D-8520-3BA168541D6E

Q37248327-153879A3-EDBF-4170-BD06-B9FCD29187BA

Q37248327-21D4B3D3-815F-4E36-A654-2FCE41D11B8C

Q37248327-2240170D-4B62-48ED-B633-057C57063F79

Q37248327-35328539-ACFE-4AC2-B4BD-97BA21C4335D

Q37248327-5A09FA35-7CB0-45A9-8B0A-F035ED1158A7

Q37248327-61C5B79D-ED43-4D0F-BD46-7D148CE5F4BC

Q37248327-8FE42887-993C-43FA-AEE2-684023050201

Q37248327-943A7E21-F648-4AEA-A4AB-40357F25EACE

Q37248327-9C5D13D2-1918-42B5-98AF-F608E94F5CD2

P304

Q37248327-A3C4E9C7-B160-4A8E-A2E4-45F84CEA7916

P31

Q37248327-DC881A69-5F3D-4D0B-9A55-A35A5AD8F223

P356

Q37248327-85900348-D822-44D6-9586-626604170678

P433

Q37248327-B1A832FE-49AC-48E0-B10E-A818C84F5D65

P478

Q37248327-0BF06C20-D287-4393-AC26-9F64F8DE89F6

P50

Q37248327-19C8C985-1EF1-43E8-90A9-3A57125EF125

Q37248327-719142C9-5FAE-4108-813A-C70E3702846A

Q37248327-72A4CFC9-EA03-4DF8-89F3-EC7E5E380AA3

Q37248327-A57E8723-8282-44F6-8858-6B4350FA3A66

P577

Q37248327-78FCB17A-1876-41EC-8122-4EB746C6C078

P5875

Q37248327-A4C67BE5-244A-4CAB-95F2-DE63451CFDEA

P698

Q37248327-5F36797A-00B2-4016-BF9C-92FA4230E057

P921

Q37248327-117E485C-E043-4808-A34D-8C0E97F473A3

P932

Q37248327-84ECE64F-AEED-4B92-AC30-0FF30BEF99A1

P356

J.1600-0609.2009.01257.X

P1433

European Journal of Haematology

P1476

Lenalidomide in combination wi ...... or refractory multiple myeloma

@en

P2093

Andrew Belch

http://www.w3.org/2001/XMLSchema#string

Donna M Weber

http://www.w3.org/2001/XMLSchema#string

Edward A Stadtmauer

http://www.w3.org/2001/XMLSchema#string

Jerome B Zeldis

http://www.w3.org/2001/XMLSchema#string

Marta Olesnyckyj

http://www.w3.org/2001/XMLSchema#string

Miles H Prince

http://www.w3.org/2001/XMLSchema#string

Robert D Knight

http://www.w3.org/2001/XMLSchema#string

Zhinuan Yu

http://www.w3.org/2001/XMLSchema#string

P2860

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Antitumor activity of thalidomide in refractory multiple myeloma.

International uniform response criteria for multiple myeloma.

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.

Current treatment options for myeloma.

Thalidomide for treatment of multiple myeloma: 10 years later.

Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma.

P304

426-432

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1600-0609.2009.01257.X

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

82

http://www.w3.org/2001/XMLSchema#string

P50

Meletios A. Dimopoulos

Jesus San Miguel

Ruben Niesvizky

P577

2009-03-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24216239

http://www.w3.org/2001/XMLSchema#string

P698

19302559

http://www.w3.org/2001/XMLSchema#string

P921

P932

2704925

http://www.w3.org/2001/XMLSchema#string